<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00800358</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol No: CT 08-02</org_study_id>
    <nct_id>NCT00800358</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Paricalcitol Versus Calcitriol in the Treatment of Secondary Hyperparathyroidism</brief_title>
  <official_title>A Multi Centre, Open Label, Parallel Group, Randomized Controlled Trial to Compare the Safety and Efficacy of Oral Paricalcitol Versus Oral Calcitriol in the Treatment of Secondary Hyperparathyroidism in Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Penang Hospital, Malaysia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Malaysia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Penang Hospital, Malaysia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether oral paricalcitol is safer and more
      efficacious compared to oral calcitriol in the treatment of hyperparathyroidism in chronic
      kidney disease patients undergoing dialysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary hyperparathyroidism, a common consequence of chronic kidney disease, results from
      abnormal regulation of calcium and phosphate homeostasis. The early administration of calcium
      supplements or vitamin D attenuates the development and progression of hyperparathyroidism,
      preventing or retarding the emergence of many of the serious complications of chronic kidney
      disease. However, these vitamin D derivatives also have serious side effects, including
      hypercalcemia and hyperphosphatemia and, as a result, a high level of the calcium-phosphate
      product. These adverse outcomes have prompted the development of novel, &quot;nonhypercalcemic&quot;
      vitamin D analogues. Three of these analogues have recently been marketed for clinical use in
      patients with chronic kidney disease: 19-nor-1,25-dihydroxyvitamin D2 (paricalcitol), 1
      -hydroxyvitamin D2 (doxercalciferol), and 22-oxacalcitriol.

      Oral paricalcitol was developed to provide a convenient, alternative therapy, particularly
      for Peritoneal Dialysis patients in whom regular intravenous administration of paricalcitol
      is not practical. This study is designed to determine the proportion of patients with 'End
      stage renal failure' on haemodialysis or peritoneal dialysis and secondary
      hyperparathyroidism who achieved more than 30% reduction in baseline iPTH concentration at 24
      weeks of treatment with Paricalcitol or Calcitriol capsules.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>More than 30% reduction in baseline iPTH concentration at 24 weeks of treatment with Paricalcitol or Calcitriol capsules.</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantum of reduction in alkaline phosphatase level, Time duration to achieve the target level of iPTH. (Titration time), Serum Calcium, phosphate, Ca x Po4 product change from baseline</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypercalcaemic episodes</measure>
    <time_frame>Through out 24 weeks of participation from the time of enrollment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Hyperparathyroidism</condition>
  <condition>Kidney Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Paricalcitol in varying doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Calcitriol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paricalitol</intervention_name>
    <description>oral paricalcitol variable daily dosing based on intact PTH level for 6 months</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Zemplar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcitriol</intervention_name>
    <description>oral calcitriol variable daily dosing based on intact PTH level for 6 months</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age at or above 18 years

          -  End stage renal disease on regular maintenance haemodialysis or peritoneal dialysis
             for at least 3 months

          -  iPTH level of 300 pg/ml or greater at baseline

          -  Written informed consent by subject or guardian

          -  Female patients will either be post-menopausal for more than 2 years, surgically
             sterile or if of childbearing age, using double contraception

        Exclusion Criteria:

          -  Baseline calcium value more than 2.87 mmol/L

          -  Baseline Ca x P of greater than 5.63 mmol2/l2

          -  Positive for HBsAg or Hepatitis C with raised ALT twice above upper limit of normal or
             evidence of liver cirrhosis

          -  Clinically significant gastrointestinal disease

          -  History of allergic reaction to calcitriol or other vitamin D compounds

          -  Inability or unwillingness to provide written consent.

          -  Inability or unwillingness to comply with the requirements of the protocol as
             determined by the investigator.

          -  Pregnancy, breastfeeding or use of non-reliable method of contraception.

          -  Use of medications prohibited prior to randomization such as ketoconazole and other
             strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir,
             itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir

          -  Necessity for calcitonin, biphosphonates, maintenance oral or intravenous
             glucocorticoid or cinacalcet or other drugs that may affect calcium or bone
             metabolism.

          -  Alcohol or substance abuse within 6 months prior to screening

          -  Other medical condition which, in the investigator's judgement, may be associated with
             increased risk to the subject or may interfere with study assessments or outcomes.

          -  Participation in another clinical trial and/or receipt of investigational drugs within
             4 weeks prior to screening visit.

          -  If PD subjects had active peritonitis within one month prior to the screening visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ong L Meng, MBBS, MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Centre, Penang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Sultanah Bahiyah Haemodialysis Unit KM 6 Jalan Langgar</name>
      <address>
        <city>Alor Star</city>
        <state>Kedah</state>
        <zip>05460</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hemodialysis Unit, Raja Perempuan Zainab II Hospital</name>
      <address>
        <city>Kota Bahru</city>
        <state>Kelantan</state>
        <zip>15586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hemodialysis Unit, Tengku Ampuan Afzan Hospital</name>
      <address>
        <city>Kuantan</city>
        <state>Pahang</state>
        <zip>25100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Centre, Penang Hospital</name>
      <address>
        <city>Georgetown</city>
        <state>Penang</state>
        <zip>10990</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haemodialysis Unit, Seberang Jaya Hospital</name>
      <address>
        <city>Seberang jaya</city>
        <state>Penang</state>
        <zip>13700</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hemodialysis Unit, Taiping Hospital</name>
      <address>
        <city>Taiping</city>
        <state>Perak</state>
        <zip>34000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nephrology Department, Tengku Ampuan Rahimah Hospital</name>
      <address>
        <city>Klang</city>
        <state>Selangor</state>
        <zip>41200</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hemodialysis Unit, Kuala Lumpur Hospital</name>
      <address>
        <city>Kuala Lumpur</city>
        <state>Selangor</state>
        <zip>50586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haemodialysis Unit, Serdang Hospital</name>
      <address>
        <city>Serdang</city>
        <state>Selangor</state>
        <zip>43000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hemodialysis Unit, Tuanku Ja'afar Seremban Hospital</name>
      <address>
        <city>Seremban</city>
        <state>Selangor</state>
        <zip>70300</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haemodialysis Unit, Melaka Hospital</name>
      <address>
        <city>Melaka</city>
        <zip>75400</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2008</study_first_submitted>
  <study_first_submitted_qc>December 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2008</study_first_posted>
  <last_update_submitted>December 4, 2012</last_update_submitted>
  <last_update_submitted_qc>December 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Penang Hospital, Malaysia</investigator_affiliation>
    <investigator_full_name>Dr.Ong Loke Meng</investigator_full_name>
    <investigator_title>Consultant Nephrologist</investigator_title>
  </responsible_party>
  <keyword>Secondary hyperparathyroidism</keyword>
  <keyword>End stage renal disease</keyword>
  <keyword>Haemodialysis</keyword>
  <keyword>Peritoneal dialysis</keyword>
  <keyword>Paricalcitol (Zemplar)</keyword>
  <keyword>Calcitriol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitriol</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

